22-41092999-T-G
Variant names:
Variant summary
Our verdict is Likely benign. The variant received -1 ACMG points: 2P and 3B. PM2BP4_ModerateBP6
The NM_001429.4(EP300):c.-6T>G variant causes a 5 prime UTR change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (no stars).
Frequency
Genomes: not found (cov: 32)
Consequence
EP300
NM_001429.4 5_prime_UTR
NM_001429.4 5_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: 6.31
Publications
1 publications found
Genes affected
EP300 (HGNC:3373): (E1A binding protein p300) This gene encodes the adenovirus E1A-associated cellular p300 transcriptional co-activator protein. It functions as histone acetyltransferase that regulates transcription via chromatin remodeling and is important in the processes of cell proliferation and differentiation. It mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. This gene has also been identified as a co-activator of HIF1A (hypoxia-inducible factor 1 alpha), and thus plays a role in the stimulation of hypoxia-induced genes such as VEGF. Defects in this gene are a cause of Rubinstein-Taybi syndrome and may also play a role in epithelial cancer. [provided by RefSeq, Jul 2008]
EP300 Gene-Disease associations (from GenCC):
- Rubinstein-Taybi syndromeInheritance: AD Classification: DEFINITIVE Submitted by: Illumina
- Rubinstein-Taybi syndrome due to EP300 haploinsufficiencyInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, G2P, Labcorp Genetics (formerly Invitae), ClinGen
- retinitis pigmentosaInheritance: AD Classification: LIMITED Submitted by: G2P
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Likely_benign. The variant received -1 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.38).
BP6
Variant 22-41092999-T-G is Benign according to our data. Variant chr22-41092999-T-G is described in ClinVar as Likely_benign. ClinVar VariationId is 3354336.Status of the report is no_assertion_criteria_provided, 0 stars.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_001429.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| EP300 | NM_001429.4 | MANE Select | c.-6T>G | 5_prime_UTR | Exon 1 of 31 | NP_001420.2 | Q09472 | ||
| EP300 | NM_001362843.2 | c.-6T>G | 5_prime_UTR | Exon 1 of 30 | NP_001349772.1 | A0A669KB12 |
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| EP300 | ENST00000263253.9 | TSL:1 MANE Select | c.-6T>G | 5_prime_UTR | Exon 1 of 31 | ENSP00000263253.7 | Q09472 | ||
| EP300 | ENST00000916082.1 | c.-6T>G | 5_prime_UTR | Exon 1 of 31 | ENSP00000586141.1 | ||||
| EP300 | ENST00000715703.1 | c.-6T>G | 5_prime_UTR | Exon 1 of 31 | ENSP00000520505.1 | Q09472 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Cov.: 31
GnomAD4 exome
Cov.:
31
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
Alfa
AF:
Hom.:
ClinVar
ClinVar submissions
View on ClinVar Significance:Likely benign
Revision:no assertion criteria provided
Pathogenic
VUS
Benign
Condition
-
-
1
EP300-related disorder (1)
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.